Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05089331 · ClinicalTrials.gov registry record
ROSE-Longitudinal Assessment With Neuroimaging
A clinical trial of Intracerebral Hemorrhage, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- 250
- Enrollment target
- 7
- Study locations
NCT05089331: Recruiting study of Intracerebral Hemorrhage, sponsored by State University of New York at Buffalo.
NCT05089331 is a study of Intracerebral Hemorrhage that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 250 participants, below the 1,098-participant average among 31 other Intracerebral Hemorrhage trials with a reported enrollment target (77% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05089331, a study of Intracerebral Hemorrhage, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 7
- Study locations
Study Summary
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date.
Primary Outcome
Each subject has a baseline # Tesla (3T) MRI with DTI along with blinded central measurement of cerebral small vessel disease parameters. The current proposal is specifically designed to address these potential hypotheses by a comprehensive evaluation of detailed neurocognitive evaluations, baseline and long-term follow-up neuroimaging markers of CSVD and CAA as well as RNA sequencing of serum leukocytes for markers of inflammation.
Conditions Studied
Study Locations (7)
Illinois
- University of Illinois Chicago - Chicago
Kentucky
- Baptist Health Louisville - Louisville
Maryland
- University of Maryland - Baltimore
New York
- Columbia University - New York
North Carolina
- Duke University - Durham
Ohio
- University of Cincinnati - Cincinnati
Texas
- Houston Methodist - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2026-06-01 |
What NCT05089331 shows while recruiting
NCT05089331 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,098-participant average among 31 other Intracerebral Hemorrhage trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 0 interventions.
NCT05089331 lists 7 locations in 7 states (Illinois, Kentucky, Maryland).
Frequently Asked Questions
What is clinical trial NCT05089331 about?
NCT05089331 is a clinical study titled "ROSE-Longitudinal Assessment With Neuroimaging". The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 ...
What is the current status of trial NCT05089331?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2020-09-30. Estimated completion is 2026-06-01.
What conditions does trial NCT05089331 study?
This clinical trial studies the following conditions: Intracerebral Hemorrhage.
Who is sponsoring clinical trial NCT05089331?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05089331 being conducted?
This trial has 7 study locations across Illinois, Kentucky, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracerebral Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05089331's enrollment target sits among peer trials
250 16th of 31 higher than 16 of 31 other Intracerebral Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Intracerebral Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hemodynamic ABI Monitor
RECRUITING
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
RECRUITING · Phase 3
-
Transitions of Care for Stroke Patients
RECRUITING
-
International Care Bundle Evaluation in Cerebral Hemorrhage Research
RECRUITING · Phase 4
-
Optical Coherence Tomography Angiography in Neurological Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI